Skip to content

Exoskeletons for Spinal Cord Injury: A Feasibility Study

An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalk™ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01943669
Enrollment
10
Registered
2013-09-17
Start date
2013-06-30
Completion date
2013-12-31
Last updated
2013-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Keywords

Spinal Cord Injury

Brief summary

In this study, 10 volunteer participants with chronic spinal cord injury will undergo a 10-week training schedule for ambulation with the ReWalk™ device. The ReWalk™ consists of a lightweight brace-support suit containing motors at the hip and knee joints, rechargeable batteries and a computerized control system carried in a backpack. ReWalk™ users control their ambulation through subtle changes in centre of gravity and upper-body movements. Before, during and after training sessions the volunteers will perform standardised assessments and complete questionnaires to assess the functional and psychological effects of the exoskeleton. Functional outcomes primarily focus on ambulation outcomes and psychological outcomes primarily focus on predisposition and perceptions of disability. The outcomes of this pilot study will assist the investigators in the preparations of randomised controlled trail for assessing the efficacy of the ReWalk™ device in a neurorehabilitation setting.

Detailed description

In this study, 10 volunteer participants with chronic spinal cord injury will undergo a 10-week training schedule for ambulation with the ReWalk™ device. The ReWalk™ consists of a lightweight brace-support suit containing motors at the hip and knee joints, rechargeable batteries and a computerized control system carried in a backpack. ReWalk™ users control their ambulation through subtle changes in centre of gravity and upper-body movements. Before, during and after training sessions the volunteers will perform standardised assessments and complete questionnaires to assess the functional and psychological effects of the exoskeleton. Twenty one-hour training sessions are scheduled for each participant over a 10-week period. Functional outcomes primarily focus on ambulation outcomes and psychological outcomes primarily focus on predisposition and perceptions of disability. The outcomes of this pilot study will assist the investigators in the preparations of randomised controlled trail for assessing the efficacy of the ReWalk™ device in a neurorehabilitation setting.

Interventions

DEVICEReWalk™ device

Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.

Sponsors

Buckinghamshire Healthcare NHS Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A, B & C (Lower Extremity Motor Score \<20) * Motor level of injury from Cervical level 7 to Lumbar level 1, according to ASIA guidelines * Male and non-pregnant, non-lactating female * Age 18-55 years old * At least 12 months after injury * Able to stand or maintain upright position with or without using a standing device (e.g., 'Easy stand') * Able to sit with hips and knees ≥90° flexion * Height of 160 to 190 cm * Weight of \<100 kg

Exclusion criteria

* History of severe neurological injuries other than spinal cord injury (eg. Multiple Sclerosis, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke) * Concurrent medical diseases (eg. infections, circulatory, heart or lung, pressure sores) interfering with the study * Unstable spine or unhealed limbs or pelvic fractures * Limited range of motion (\<90°) hip and knee joints, including severe contractures * Severe spasticity (Ashworth grade 4; ie. Affected part(s) rigid in flexion or extension) or uncontrolled clonus * Diagnosis of severe osteoporosis/penia as proven with pQCT or DXA. * Psychiatric or cognitive conditions that may interfere with the trial * Previous use of any exoskeletal robotic device * Patients incapable of providing informed consent

Design outcomes

Primary

MeasureTime frameDescription
10-meter walking test (10MWT)10 weeksChange in score between 0 and 10 weeks.

Secondary

MeasureTime frameDescription
6-minutes walk test (6MWT)10 weeksChange in score between 0 and 10 weeks.
Timed Up and Go (TUG) test10 weeksChange in score between 0 and 10 weeks.
Assistive Technology Device Predisposition Assessment© (ATDPA) Questionnaire10 weeksChange in score between 0 and 10 weeks.
Appraisals of Disability: Primary and Secondary Scale (ADAPSS) Questionnaire10 weeksChange in score between 0 and 10 weeks.

Other

MeasureTime frameDescription
Stair management10 weeksExact timing pending learning curve, change in score in weeks up to 10 weeks.
Obstacle course10 weeksExact timing pending learning curve, change in score in weeks up to 10 weeks.

Countries

United Kingdom

Contacts

Primary ContactJoost J. van Middendorp, MD, PhD
Joost.vanMiddendorp@buckshealthcare.nhs.uk+44 1296 316783

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026